As a new year begins, plans are underway for the 8 th Annual Rare Disease Genomics Symposium to be held on February 26 th and 27 th. The two-day event will be virtual this year to limit the spread of ...

CHICAGO -- Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial ...

This month, our discussion focuses on the clinical management of plexiform neurofibromas in the era of selumetinib, a MEK inhibitor medication that was approved by the FDA in 2020 for the treatment of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Mirdametinib is an investigational mitogen-activated ...

A new preclinical model of pulmonary arterial hypertension (PAH) may lead to improved research and ultimately better therapies for this life-threatening problem, according to its developers. A new ...

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements. The ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Koselugo’s approval was based on data from the phase 3 ...

Findings from the ReNeu trial showed treatment with mirdametinib resulted in statistically significant objective response rates. The Food and Drug Administration (FDA) has accepted for Priority Review ...

Dublin, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The "Plexiform Neurofibroma Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035" has been added to ResearchAndMarkets.com's ...

At its May 2025 meeting, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a conditional marketing authorization for mirdametinib (Ezmekly, Springworks ...

Neurofibromatosis Type 1 (NF1) is an autosomal dominant disorder that commonly presents with ophthalmic lesions. 1 We would like to present a case of a patient with previously undiagnosed NF1 ...